Massive Losses for Intercell

Companies › Health Care ♦ Published: March 2, 2011; 00:00 ♦ (Vindobona)

The Austrian pharmaceutical company today reported losses for 2010 amounting to € 255m. Operating cash flow has been strongly negative too.

Massive Losses for Intercell / Picture: © Vindobona.org

Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company’s development programs.

In 2010, Intercell experienced a serious backdrop in its development. Due to a cancelled program for the development of vaccines, the company had to…

or Log In

Fast News Search
Related News
Intercell Issues Convertible Bond (February 23, 2011)
Intercell Raises Authorized Capital (December 16, 2010)
Serious setback for Intercell (December 14, 2010)
Economic Chamber in Tokyo: Biotechnology as an Opportunity (December 6, 2010)
Intercell AG: Losses Doubled, Positive Outlook (November 9, 2010)
Read More
Intercell, Earnings, Health Policy, Pharmaceutical Industry
Featured
Coronavirus in Austria: Update
Coronavirus Situation at the Vienna International Centre (VIC): Live-Ticker - New COVID-19 Case at the IAEA
See latest Vindobona Newsletter